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Angiopoietin-Like 3 From Discovery to Therapeutic Gene Editing
Xiao Wang, PHD, Kiran Musunuru, MD, PHD, MPH, ML HIGHLIGHTS Individuals with ANGPTL3 loss-of-function mutations have reduced cholesterol levels, triglyceride levels, and risk of coronary heart disease, making ANGPTL3 a potential therapeutic target.
An antisense oligonucleotide inhibitor of ANGPTL3 and a monoclonal antibody against ANGPTL3 have been advanced into clinical trials, with encouraging results to date.
A distinct approach to targeting ANGPTL3 would be therapeutic gene editing in patients to induce permanent loss of function mutations mimicking those in individuals with naturally occurring cardioprotective mutations.
SUMMARY
Hyperlipidemia is a major causal risk factor for atherosclerosis and coronary heart disease (CHD). Angiopoietin-like 3 (ANGPTL3) has emerged as a promising molecular target to reduce CHD risk due to its regulation of all 3 major lipid traits: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Here, the authors review the discovery of ANGPTL3, the role of ANGPTL3 in lipoprotein metabolism, and the genetic association between naturally occurring ANGPTL3 loss-of-function mutations and CHD. In light of the favorable consequences of ANGPTL3 deficiency, O ver the last few decades, tremendous progress has been made in understanding and decreasing the incidence of coronary heart disease (CHD). Low-density lipoprotein cholesterol (LDL-C) has been established as a major causal risk factor for atherosclerosis and CHD. Remarkable efforts have been made to develop LDL-lowering therapies, and statins have been proven to be an effective means of reducing the risk of CHD. However, even with the use of statin therapy, there remains a large residual risk of CHD, particularly in patients with familial hypercholesterolemia (1) . In light of these observations, an intensive search for new molecular targets to further reduce CHD risk is ongoing. In 2015, the efficacy of alirocumab and evolocumab, 2 human monoclonal antibody-based drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9), was confirmed with respect to the reduction of LDL-C levels in patients (2, 3) .
Despite advances in the development of lipidlowering therapies, clinical trials have shown that a substantial risk of cardiovascular disease persists even when receiving currently recommended medical therapy. For example, in 1 trial involving patients who had an acute coronary syndrome, the lowering of LDL-C levels to a median of 54 mg/dl with the use of a statin plus ezetimibe was found to prevent only a slightly higher proportion of events than treatment with a statin alone; the difference in absolute risk associated with the 2 regimens was only 2 proportion points, and approximately one-third of both sets of patients had a major cardiovascular event within 7 years (4). A similarly small reduction in the absolute risk of coronary events was found among patients whose levels of LDL-C were reduced to 30 mg/dl with the use of a PCSK9 inhibitor (5) . In addition, researchers have continued to search for additional molecular targets that are particularly relevant for the treatment of patients with homozygous familial hypercholesterolemia (hoFH) who have genetic deficiency of the LDL receptor. Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to both therapies.
One such promising molecular target is angiopoietin-like 3 (ANGPTL3). ANGPTL3 belongs to a is secreted from liver and was first identified via positional cloning of a hypolipidemic mouse strain (6) .
ANGPTL3 is unique in that it regulates all 3 major lipid traits: LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides. The primary action of ANGPTL3 is to inhibit lipoprotein lipase (LPL), which hydrolyzes the triglycerides carried in triglyceriderich lipoproteins in the circulation (7) . ANGPTL3 also inhibits endothelial lipase to modulate HDL-C metabolism (8) . The mechanism by which ANGPTL3 regulates LDL-C remains unclear (9) .
DISCOVERY OF ANGPTL3
The Similar to other angiopoietin-like proteins, ANGPTL3 undergoes cleavage; the cleavage site is at amino acid residues 221-Arg-Ala-Pro-Arg-224, which yields separate fragments containing the coiled-coil domain and the FLD (12) . ANGPTL3 is found in the plasma as fulllength and truncated forms. ANGPTL3 is cleaved intracellularly by furin (also known as PCSK3) and extracellularly mainly by PACE4 (also known as PCSK6) (13) . The truncated form of ANGPTL3 is more active, and cleavage enhances the ability of ANGPTL3 to inhibit lipoprotein lipase and regulate plasma levels of triglycerides both in vitro (11) and in vivo (12) .
Similar to ANGPTL3, another 2 members of the angiopoietin-like protein family-ANGPTL4 and ANGPTL8-are involved in the regulation of plasma lipid metabolism.
ANGPTL4 is highly expressed in the liver and adipose tissue and upregulated by fasting and hypoxia (14, 15) . ANGPTL4 forms dimers and tetramers before secretion and undergoes cleavage at a canonical proprotein convertase cleavage site, 161-Arg-Arg-Lys-Arg-164, after secretion (16) . The N-terminal fragment remains oligomerized after cleavage, binds transiently to LPL, and converts LPL from catalytically active dimers to inactive monomers to decrease its activity (17) .
Angptl4 knockout mice have lower triglyceride levels and modestly lower cholesterol levels (18) . However, when Angptl4 knockout mice were fed a high-fat diet, they showed reduced viability associated with lipogranulomatous lesions, which raises a significant safety concern with respect to the proposed targeting of ANGPTL4 for the treatment of dyslipidemia and atherosclerosis (18, 19) .
ANGPTL8 is an atypical member of the angiopoietin-like protein family because of its lack of a C-terminal FLD, but it does share structural homology with the N-terminal domains of ANGPTL3 and ANGPTL4 (20, 21) , and it can inhibit LPL and thereby regulate triglyceride metabolism (11) .
ANGPTL3 GENETICS AND PLASMA LIPIDS. Genomewide association studies and exome sequencing studies have identified associations between loss-offunction genetic variants in the ANGPTL3 gene and low levels of plasma LDL-C, HDL-C, and triglycerides (22, 23) . The ANGPTL3 coding regions were sequenced They received the antibody for 4 weeks, and their LDL-C levels were decreased by w50% at week 4, although the patients were already taking aggressive lipid-lowering therapy (32) .
ANGPTL3 AND THERAPEUTIC GENE EDITING.
Another approach to target ANGPTL3 is via gene has matching sequence to the site of the break but also has a custom-made DNA mutation, the mutation can be introduced into the genome. However, introducing a specific mutation at the site with HDR is usually inefficient, and the efficiency in vivo in adult animals is very low (<1%), which limits its use to correct a disease-causing mutation (35) . Another major concern about using a gene editor is that it might also cleave the genome at other sites and cause off-target mutations.
To circumvent these problems, CRISPR-Cas9 has been adapted so that it can directly alter specific nucleotides in the DNA sequence without generating double-strand breaks and without the need for a repair template-a phenomenon known as base editing (36) (37) (38) (39) (40) tions, which is easier to achieve than precisely correcting a specific gene mutation.
Will in vivo gene editing approaches translate into the clinic and provide a potential preventive strategy for CHD in humans? The primary benefit of in vivo gene editing is that it could ultimately yield a 1-shot, long-term therapy that would permanently modify a target gene, removing the need for repeated administration of drugs. Before consideration of translation into the clinic, ethical and regulatory challenges as well as technical issues must be addressed.
The first concern about in vivo gene editing from the scientific community has been the potential for off-target mutagenesis. It has the potential to introduce unanticipated mutations that cause oncogenesis, promoting a different disease than the 1 being treated. Second, unintended on-target mutagenesis requires more characterization before gene editing can be used as a therapy in humans because it causes irreversible genetic changes with possible serious adverse effects. Third, there might be the potential for toxicity or immune responses on delivery, and methods of safe delivery will need to be refined.
Adeno-associated viruses are the preferred viral delivery vehicle compared with adenoviral vectors for use in humans because of safety concerns (42, 43) .
However, the size limitation of each adeno-associated virus vector makes it challenging to deliver a gene editor, especially a base editor. A nonviral solution would be the use of lipid nanoparticles to deliver gene editing tools into hepatocytes (44, 45) .
Despite these challenges, ANGPTL3 is a promising gene editing target for potential clinical translation. The best candidates for first-in-human studies would be hoFH patients because they show limited response to current LDL-lowering therapies and the potential benefits might substantially outweigh the risks. With a demonstration of efficacy as well as safety in these selected patients, gene-editing therapies could then be considered for broader groups of patients at risk for CHD. 
